ALENTIS

Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need... We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies... We have developed a promising pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and antibodies. Our clinical candidates include ADC ALE.P02 for squamous cancers and monoclonal antibody lixudebart for organ fibrosis. Beyond the clinical assets, our preclinical programs feature other anti-Claudin-1 modalities including other ADCs.

Primary location: Allschwil Switzerland